Home » Reports » Broker Ratings » Hikma Pharmaceuticals Plc 2.8% Potential Decrease Indicated by Barclays Capital
broker ratings

Hikma Pharmaceuticals Plc 2.8% Potential Decrease Indicated by Barclays Capital

Hikma Pharmaceuticals Plc using EPIC/TICKER code (LON:HIK) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘EQUAL WEIGHT’ this morning by analysts at Barclays Capital. Hikma Pharmaceuticals Plc are listed in the Health Care sector within UK Main Market. Barclays Capital have set a target price of 1950 GBX on its stock. This now indicates the analyst believes there is a potential downside of -2.8% from today’s opening price of 2007 GBX. Over the last 30 and 90 trading days the company share price has increased 189.5 points and increased 351 points respectively. The 52 week high for the share price is currently at 2089 GBX while the year low stock price is currently 814.2 GBX.

Hikma Pharmaceuticals Plc has a 50 day moving average of 1,896.65 GBX and the 200 Day Moving Average price is recorded at 1,488.56. There are currently 241,445,043 shares in issue with the average daily volume traded being 711,115. Market capitalisation for LON:HIK is £4,667,132,565 GBP.